Details on P2a and exactly what it is.

Update on the Abstracts & Sponsors. Abstracts will be posted before July 13th

Relfection on earnings, and exactly why industry will use the OBDS like candy

Preecludia uncertainty is no longer. The product has been reviewed and Progenity's credibility is restored

Insights onto the multi-billion dollar product lines of Progenity. Update on their progress from their flagship therapeutic pill.

IL6 suppressant (Tocilizumab) could potentially be used with Progenity's pill to capture $2.5 Billion Annually. DDS | Future applications

This shows the analysis of the future revenue of Progenity and future share price

Description of the studies for you knowledge and how it will effect share price upon release of results

Data is around the corner, details on what to look for and what to expect. Why this pill tech will disrupt healthcare

Itinerary and landing page to discussion of Progenity every wednesday evening at 7pm central time. Audio recording is uploaded afterwards

The future timeline for the adoption of Progenity's products. S-curve uptrend starts this December.

Itinerary for upcoming Twitter Spaces call

Clarification on the product lines for Progenity and near term catalysts in the future.

Progenity to dominate the market during end of year. Price appreciation is on the horizon due to market reevaluation and catalysts ahead.

Optifinancial Newsletter - Knowledge is power - Brad Mitchell This is not financial advice nor recommendations. This is purely our own...

IN THIS ISSUE Progenity $1.79 Possible short squeeze ahead, alongside strong disruptive technology in the medical field. Look at my last...

IN THIS ISSUE Progenity This small biotechnology company has fallen from $15 a share to $1 a share in one year. We think this can go to...

IN THIS ISSUE Progenity This company is developing groundbreaking medical technology. Learn why we think now is a good time to buy....

Please subscribe to us, we are worth your time and will keep you informed! RECAP OF LAST WEEK AND RESULTS: Cassava Sciences This company...